![](https://cdn.sanity.io/images/0vv8moc6/genetherapy/83c65238f611d551221eaf7cd84c7b4e114d97ee-300x300.jpg?fit=crop&auto=format)
Ixo-vec Yields Potentially Best-in-Class VEGF Injection Reduction for Wet AMD
Ixoberogene soroparvovec (ixo-vec) gene therapy has demonstrated potentially best-in-class percentage of patients with wet age-related macular degeneration (AMD) remaining free of anti-vascular endothelial growth factor (VEGF) injections and reduction in …